Browsing Tag
Obesity Drugs
15 posts
Is the next wave of obesity drugs moving beyond GLP-1? What Palatin, Rhythm, and Zealand are betting on
Explore how Palatin Technologies, Rhythm Pharmaceuticals, and Zealand Pharma are shifting obesity drug development beyond GLP-1 into MC4R and amylin pathways. Read on.
Pfizer sweetens Metsera acquisition offer to secure board approval and fend off Novo Nordisk challenge
Find out how Pfizer’s amended $86.25-per-share merger with Metsera reshapes the obesity-drug race and signals Big Pharma’s shifting acquisition strategy.
Eli Lilly lifts 2025 outlook after Zepbound and Mounjaro drive 38% Q2 revenue surge
Eli Lilly’s Q2 2025 revenue jumped 38% to $15.56 billion, led by Zepbound and Mounjaro. Read how product growth is reshaping guidance.
Which biotech companies are developing next-gen GLP-1 alternatives—and can they compete with Novo Nordisk and Eli Lilly by 2030?
Discover how biotech players like Viking, Structure, and Altimmune are developing next-gen GLP-1 drugs to challenge obesity leaders Novo Nordisk and Eli Lilly. Read more.
Novo Nordisk stock climbs 1.52% as obesity drug Liraglutide shows promise in young kids
Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data…